<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03765957</url>
  </required_header>
  <id_info>
    <org_study_id>2018-MSC/CSU/PS</org_study_id>
    <nct_id>NCT03765957</nct_id>
  </id_info>
  <brief_title>Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells</brief_title>
  <official_title>Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect and safety of treatment of psoriasis by human umbilical cord-derived&#xD;
      mesenchymal stem cel&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a chronic and recurrent inflammatory skin disease and its histological features&#xD;
      are characterized by epidermal hyperplasia, increased angiogenesis and immune cell&#xD;
      infiltration. Psoriasis prevalence is about 0.1%-3%, affecting approximately 125 million&#xD;
      people worldwide. In China, there are about 10 million psoriasis patients.&#xD;
&#xD;
      Human umbilical cord-derived MSC (huc-MSC) has many advantages for the treatment of immune&#xD;
      disease. Because it was demonstrated that huc-MSCs are effective in modulating immune cells&#xD;
      and treating diseases and it has low immunogenicity. Furthermore, huc-MSCs do not raise&#xD;
      ethical issue for clinical applications.&#xD;
&#xD;
      Some experimental results and cases has showed that mesenchymal stem cell (MSC) can prevent&#xD;
      or treat psoriasis. This clinical study is conducted to provide more data to evaluate the&#xD;
      effect and safety of treatment of psoriasis by human umbilical cord-derived mesenchymal stem&#xD;
      cell.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement</measure>
    <time_frame>Month 6</time_frame>
    <description>The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving a Physician Global Assessment (PGA) of (0, 1)</measure>
    <time_frame>Month 6</time_frame>
    <description>The PGA is a physician's determination of the participant's psoriasis lesions overall categorized by descriptions for induration, erythema, and scaling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;not at all,&quot; &quot;a lot,&quot; and &quot;very much,&quot; with corresponding scores of 1, 2, and 3, respectively, and unanswered (&quot;not relevant&quot;) responses scored as &quot;0.&quot; Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cells</intervention_name>
    <description>After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.</description>
    <arm_group_label>Mesenchymal Stem Cells</arm_group_label>
    <other_name>Human Umbilical Cord-derived Mesenchymal Stem Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Understanding the whole process of the study, voluntary participation and signed the&#xD;
        informed consent; 2.18 Years to 65 Years old, Body Mass Index (BMI) between 18.5-35;&#xD;
        3.Diagnosed according to biopsy for Psoriasis vulgaris for more than 6 months and&#xD;
        resistance to phototherapy, systemic therapy, or a combination of these therapies,BSA(body&#xD;
        surface area)&gt;10%, PGA≥3 and PASI&gt;10 at baseline; 4. Patients participated in any stem cell&#xD;
        therapy within 6 months;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. WBC(white blood cell count ) &lt;3.5x109/L, blood platelet count&lt;100x109/L,&#xD;
             hemoglobin&lt;100g/L serum creatinine&gt;1.5 x ULN(upper limit of normal), bilirubin &gt; 1.5 x&#xD;
             ULN(upper limit of normal), AST(SGOT,glutamic-oxalacetic&#xD;
             transaminase)/ALT(SGPT,glutamic-pyruvic transaminase) &gt;2.0 x ULN(upper limit of&#xD;
             normal);Either HIV-antibody(human immunodeficiency virus-antibody), HBV-antibody&#xD;
             (hepatitis B virus-antibody ) or syphilis antibody is positive;&#xD;
&#xD;
          2. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions&#xD;
             and the history,Patients suffering from any acute or chronic infectious diseases,&#xD;
             patients suffering from malignant tumor; Mental disorders, history of alcohol abuse,&#xD;
             drug or other substance abuse;&#xD;
&#xD;
          3. Patients who have received systemic therapy within recent one month or topical therapy&#xD;
             in two weeks;&#xD;
&#xD;
          4. Having a serious allergic history or being allergic to two or more than 2 kinds of&#xD;
             food or drugs;&#xD;
&#xD;
          5. Pregnant women, or women who ready for pregnancy or lactating; Patients participated&#xD;
             in any clinical trials within 3 months; Other cases which researchers believe that can&#xD;
             not enroll.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Chen, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mi Zhang, M.D. Ph.D</last_name>
    <phone>08615116331788</phone>
    <phone_ext>08615116331788</phone_ext>
    <email>648979182@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yehong Kuang, M.D. Ph.D</last_name>
    <phone>08613574171102</phone>
    <phone_ext>08613574171102</phone_ext>
    <email>yh_927@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Zhang, M.D. Ph.D</last_name>
      <phone>08615116331788</phone>
      <phone_ext>08615116331788</phone_ext>
      <email>648979182@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Yehong Kuang, M.D. Ph.D</last_name>
      <phone>08613574171102</phone>
      <phone_ext>08613574171102</phone_ext>
      <email>yh_927@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiang Chen, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mi Zhang, M.D. Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yehong Kuang, M.D. Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Comella K, Parlo M, Daly R, Dominessy K. First-in-man intravenous implantation of stromal vascular fraction in psoriasis: a case study. Int Med Case Rep J. 2018 Mar 21;11:59-64. doi: 10.2147/IMCRJ.S163612. eCollection 2018.</citation>
    <PMID>29606893</PMID>
  </reference>
  <reference>
    <citation>Lee YS, Sah SK, Lee JH, Seo KW, Kang KS, Kim TY. Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice. Biochem Biophys Rep. 2016 Oct 8;9:281-288. doi: 10.1016/j.bbrep.2016.10.002. eCollection 2017 Mar.</citation>
    <PMID>28956015</PMID>
  </reference>
  <reference>
    <citation>Boehncke WH, Schon MP. Psoriasis. Lancet. 2015 Sep 5;386(9997):983-94. doi: 10.1016/S0140-6736(14)61909-7. Epub 2015 May 27.</citation>
    <PMID>26025581</PMID>
  </reference>
  <reference>
    <citation>Owczarczyk-Saczonek A, Krajewska-Wlodarczyk M, Kruszewska A, Placek W, Maksymowicz W, Wojtkiewicz J. Stem Cells as Potential Candidates for Psoriasis Cell-Replacement Therapy. Int J Mol Sci. 2017 Oct 20;18(10):2182. doi: 10.3390/ijms18102182.</citation>
    <PMID>29053579</PMID>
  </reference>
  <reference>
    <citation>Guan LX, Guan H, Li HB, Ren CA, Liu L, Chu JJ, Dai LJ. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med. 2015 May;9(5):1623-1630. doi: 10.3892/etm.2015.2339. Epub 2015 Mar 9.</citation>
    <PMID>26136869</PMID>
  </reference>
  <reference>
    <citation>Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG, Kang BC, Lee YS, Nakama K, Piao M, Sohl B, Kurtz A. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med. 2011 Oct 21;9:181. doi: 10.1186/1479-5876-9-181.</citation>
    <PMID>22017805</PMID>
  </reference>
  <reference>
    <citation>Dahbour S, Jamali F, Alhattab D, Al-Radaideh A, Ababneh O, Al-Ryalat N, Al-Bdour M, Hourani B, Msallam M, Rasheed M, Huneiti A, Bahou Y, Tarawneh E, Awidi A. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci Ther. 2017 Nov;23(11):866-874. doi: 10.1111/cns.12759. Epub 2017 Sep 29.</citation>
    <PMID>28961381</PMID>
  </reference>
  <reference>
    <citation>Cui GH, Wang YY, Li CJ, Shi CH, Wang WS. Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: A meta-analysis. Exp Ther Med. 2016 Nov;12(5):3390-3400. doi: 10.3892/etm.2016.3791. Epub 2016 Oct 11.</citation>
    <PMID>27882169</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Yijing He</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03765957
org study id: 2018-MSC/CSU/PS
nct id: NCT03765957
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
To evaluate the effect and safety of treatment of psoriasis by human umbilical cord-derived
      mesenchymal stem cel
Psoriasis is a chronic and recurrent inflammatory skin disease and its histological features
      are characterized by epidermal hyperplasia, increased angiogenesis and immune cell
      infiltration. Psoriasis prevalence is about 0.1%-3%, affecting approximately 125 million
      people worldwide. In China, there are about 10 million psoriasis patients.

      Human umbilical cord-derived MSC (huc-MSC) has many advantages for the treatment of immune
      disease. Because it was demonstrated that huc-MSCs are effective in modulating immune cells
      and treating diseases and it has low immunogenicity. Furthermore, huc-MSCs do not raise
      ethical issue for clinical applications.

      Some experimental results and cases has showed that mesenchymal stem cell (MSC) can prevent
      or treat psoriasis. This clinical study is conducted to provide more data to evaluate the
      effect and safety of treatment of psoriasis by human umbilical cord-derived mesenchymal stem
      cell.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Number of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement
time frame: Month 6
description: The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 was defined as having an improvement of at least 75% in the PASI scores compared to baseline.
measure: Number of Participants Achieving a Physician Global Assessment (PGA) of (0, 1)
time frame: Month 6
description: The PGA is a physician's determination of the participant's psoriasis lesions overall categorized by descriptions for induration, erythema, and scaling.
measure: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
time frame: Baseline, Month 6
description: The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5 point change from baseline is considered clinically relevant. Least Square (LS) Means in total DLQI score were calculated using Mixed Model Repeated Measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
measure: Adverse event
time frame: Baseline, Month 6
description: An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
arm group label: Mesenchymal Stem Cells
arm group type: Experimental
description: The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment.
intervention type: Biological
intervention name: Mesenchymal Stem Cells
description: After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
arm group label: Mesenchymal Stem Cells
other name: Human Umbilical Cord-derived Mesenchymal Stem Cells
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: No
last name: Xiang Chen, M.D. Ph.D
role: Principal Investigator
affiliation: Xiangya Hospital of Central South University
last name: Mi Zhang, M.D. Ph.D
phone: 08615116331788
phone ext: 08615116331788
email: 648979182@qq.com
last name: Yehong Kuang, M.D. Ph.D
phone: 08613574171102
phone ext: 08613574171102
email: yh_927@126.com
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
country: China
citation: Comella K, Parlo M, Daly R, Dominessy K. First-in-man intravenous implantation of stromal vascular fraction in psoriasis: a case study. Int Med Case Rep J. 2018 Mar 21;11:59-64. doi: 10.2147/IMCRJ.S163612. eCollection 2018.
PMID: 29606893
citation: Lee YS, Sah SK, Lee JH, Seo KW, Kang KS, Kim TY. Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice. Biochem Biophys Rep. 2016 Oct 8;9:281-288. doi: 10.1016/j.bbrep.2016.10.002. eCollection 2017 Mar.
PMID: 28956015
citation: Boehncke WH, Schon MP. Psoriasis. Lancet. 2015 Sep 5;386(9997):983-94. doi: 10.1016/S0140-6736(14)61909-7. Epub 2015 May 27.
PMID: 26025581
citation: Owczarczyk-Saczonek A, Krajewska-Wlodarczyk M, Kruszewska A, Placek W, Maksymowicz W, Wojtkiewicz J. Stem Cells as Potential Candidates for Psoriasis Cell-Replacement Therapy. Int J Mol Sci. 2017 Oct 20;18(10):2182. doi: 10.3390/ijms18102182.
PMID: 29053579
citation: Guan LX, Guan H, Li HB, Ren CA, Liu L, Chu JJ, Dai LJ. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med. 2015 May;9(5):1623-1630. doi: 10.3892/etm.2015.2339. Epub 2015 Mar 9.
PMID: 26136869
citation: Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG, Kang BC, Lee YS, Nakama K, Piao M, Sohl B, Kurtz A. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med. 2011 Oct 21;9:181. doi: 10.1186/1479-5876-9-181.
PMID: 22017805
citation: Dahbour S, Jamali F, Alhattab D, Al-Radaideh A, Ababneh O, Al-Ryalat N, Al-Bdour M, Hourani B, Msallam M, Rasheed M, Huneiti A, Bahou Y, Tarawneh E, Awidi A. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci Ther. 2017 Nov;23(11):866-874. doi: 10.1111/cns.12759. Epub 2017 Sep 29.
PMID: 28961381
citation: Cui GH, Wang YY, Li CJ, Shi CH, Wang WS. Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: A meta-analysis. Exp Ther Med. 2016 Nov;12(5):3390-3400. doi: 10.3892/etm.2016.3791. Epub 2016 Oct 11.
PMID: 27882169
responsible party type: Principal Investigator
investigator affiliation: Central South University
investigator full name: Yijing He
investigator title: Associate professor
mesh term: Psoriasis
sharing ipd: Undecided